Atara Biotherapeutics, Inc. — Director's Dealing 2016

Aug 24, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Atara Biotherapeutics, Inc. (ATRA)
CIK: 0001604464
Period of Report: 2016-08-22

Reporting Person: Ciechanover Isaac E. (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-08-22	Common Stock	S	4800	$22.58	Disposed	430578	Indirect
2016-08-23	Common Stock	S	4800	$22.08	Disposed	425778	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	229136	Direct
Common Stock	180000	Indirect

Footnotes

F1: Transaction pursuant to Rule 10b5-1 Plan adopted March 22, 2016.

F2: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $22.22 to $22.94. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3: Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.

F4: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $21.65 to $22.24. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F5: Shares are held by the Ciechanover 2015 GRAT, of which the Reporting Person is a trustee.